WO2003077858A3 - Humanized antibodies that recognize beta amyloid peptide - Google Patents

Humanized antibodies that recognize beta amyloid peptide Download PDF

Info

Publication number
WO2003077858A3
WO2003077858A3 PCT/US2003/007715 US0307715W WO03077858A3 WO 2003077858 A3 WO2003077858 A3 WO 2003077858A3 US 0307715 W US0307715 W US 0307715W WO 03077858 A3 WO03077858 A3 WO 03077858A3
Authority
WO
WIPO (PCT)
Prior art keywords
humanized antibodies
amyloid peptide
beta amyloid
recognize beta
recognize
Prior art date
Application number
PCT/US2003/007715
Other languages
French (fr)
Other versions
WO2003077858A2 (en
Inventor
Guriq Basi
Jose Saldanha
Original Assignee
Neuralab Ltd
Wyeth Corp
Guriq Basi
Jose Saldanha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200401170A priority Critical patent/EA010902B1/en
Priority to ES03711559T priority patent/ES2389541T3/en
Application filed by Neuralab Ltd, Wyeth Corp, Guriq Basi, Jose Saldanha filed Critical Neuralab Ltd
Priority to IL16362603A priority patent/IL163626A0/en
Priority to EP03711559A priority patent/EP1554311B1/en
Priority to JP2003575912A priority patent/JP2006503549A/en
Priority to NZ535769A priority patent/NZ535769A/en
Priority to CN038058162A priority patent/CN1703426B/en
Priority to MXPA04008740A priority patent/MXPA04008740A/en
Priority to CA2478049A priority patent/CA2478049C/en
Priority to BRPI0308143-5A priority patent/BR0308143A/en
Priority to AU2003214152A priority patent/AU2003214152B2/en
Publication of WO2003077858A2 publication Critical patent/WO2003077858A2/en
Priority to IL163626A priority patent/IL163626A/en
Priority to NO20043992A priority patent/NO20043992L/en
Priority to IS7499A priority patent/IS7499A/en
Priority to HR20040950A priority patent/HRP20040950A2/en
Publication of WO2003077858A3 publication Critical patent/WO2003077858A3/en
Priority to HK06105249.2A priority patent/HK1085222A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
PCT/US2003/007715 2002-03-12 2003-03-12 Humanized antibodies that recognize beta amyloid peptide WO2003077858A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CN038058162A CN1703426B (en) 2002-03-12 2003-03-12 Humanized antibodies that recognize beta amyloid peptide
MXPA04008740A MXPA04008740A (en) 2002-03-12 2003-03-12 Humanized antibodies that recognize beta amyloid peptide.
IL16362603A IL163626A0 (en) 2002-03-12 2003-03-12 Humanized antibodies that recognize beta amyloid peptide
EP03711559A EP1554311B1 (en) 2002-03-12 2003-03-12 Humanized antibodies that recognize beta amyloid peptide
JP2003575912A JP2006503549A (en) 2002-03-12 2003-03-12 Humanized antibody that recognizes β-amyloid peptide
NZ535769A NZ535769A (en) 2002-03-12 2003-03-12 Humanized antibodies that recognize beta amyloid peptide
ES03711559T ES2389541T3 (en) 2002-03-12 2003-03-12 Humanized antibodies that recognize beta-amyloid peptide
EA200401170A EA010902B1 (en) 2002-03-12 2003-03-12 Humanized immunoglobulin, that recognizes beta amyloid peptide, pharmaceutical composition and method for producing thereof
CA2478049A CA2478049C (en) 2002-03-12 2003-03-12 Humanized antibodies that recognize beta amyloid peptide
AU2003214152A AU2003214152B2 (en) 2002-03-12 2003-03-12 Humanized antibodies that recognize beta amyloid peptide
BRPI0308143-5A BR0308143A (en) 2002-03-12 2003-03-12 light chain, heavy chain, immunoglobulin, humanized antibody. pharmaceutical and therapeutic composition, isolated polypeptide and peptide, polypeptide variant, isolated nucleic acid molecule, vector, host cell, transgenic animal, use of the variable region sequence presented as sequence id: 2 or sequence id. 4 and methods of preventing or treating an amyloidogenic disease associated with amyloid deposition of fir trees in a patient's brain and alzheimer's disease, of producing an antibody or fragment thereof, of identifying residues sensitive to substitution in a variable frame region of immunoglobulin , imaging of amyloid deposits in a patient's brain and reducing plaque, neuter and beta amyloid peptide (fir) load and neuritically dystrophy
IL163626A IL163626A (en) 2002-03-12 2004-08-19 Humanized antibodies that recognize beta amyloid peptide
NO20043992A NO20043992L (en) 2002-03-12 2004-09-23 Humanized antibodies that recognize beta amyloid peptide
IS7499A IS7499A (en) 2002-03-12 2004-10-11 Human antibodies against beta-amyloid peptides
HR20040950A HRP20040950A2 (en) 2002-03-12 2004-10-12 Humanized antibodies that recognize beta amyloid peptide
HK06105249.2A HK1085222A1 (en) 2002-03-12 2006-05-03 Humanized antibodies that recognize beta amyloid peptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36375102P 2002-03-12 2002-03-12
US60/363751 2002-03-12

Publications (2)

Publication Number Publication Date
WO2003077858A2 WO2003077858A2 (en) 2003-09-25
WO2003077858A3 true WO2003077858A3 (en) 2005-05-19

Family

ID=28041806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007715 WO2003077858A2 (en) 2002-03-12 2003-03-12 Humanized antibodies that recognize beta amyloid peptide

Country Status (30)

Country Link
US (2) US7256273B2 (en)
EP (1) EP1554311B1 (en)
JP (1) JP2006503549A (en)
KR (2) KR20110027846A (en)
CN (1) CN1703426B (en)
AR (1) AR038953A1 (en)
AU (1) AU2003214152B2 (en)
BR (1) BR0308143A (en)
CA (1) CA2478049C (en)
CO (1) CO5611164A2 (en)
EA (1) EA010902B1 (en)
EC (1) ECSP045314A (en)
ES (1) ES2389541T3 (en)
GE (1) GEP20084474B (en)
HK (1) HK1085222A1 (en)
HR (1) HRP20040950A2 (en)
IL (2) IL163626A0 (en)
IS (1) IS7499A (en)
MX (1) MXPA04008740A (en)
MY (1) MY139983A (en)
NO (1) NO20043992L (en)
NZ (1) NZ535769A (en)
PE (1) PE20040207A1 (en)
PL (1) PL215258B1 (en)
SG (1) SG180018A1 (en)
TW (1) TWI328116B (en)
UA (1) UA89469C2 (en)
UY (1) UY27721A1 (en)
WO (1) WO2003077858A2 (en)
ZA (1) ZA200406616B (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7871615B2 (en) 2003-05-30 2011-01-18 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7893214B2 (en) 1997-12-02 2011-02-22 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8034348B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8128928B2 (en) 2002-03-12 2012-03-06 Wyeth Llc Humanized antibodies that recognize beta amyloid peptide
US8318164B2 (en) 2005-01-28 2012-11-27 Janssen Alzheimer Immunotherapy Anti A beta antibody formulation
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
PE20020574A1 (en) * 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
CA2513722A1 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
CA2529945A1 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
US20060024667A1 (en) * 2004-07-29 2006-02-02 Karen Manucharyan Compositions and methods for Alzheimer's disease
SG190665A1 (en) * 2004-07-30 2013-06-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (en) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals Production of polypeptides
EP1797182A2 (en) * 2004-10-05 2007-06-20 Wyeth a Corporation of the State of Delaware Methods and compositions for improving recombinant protein production
TW200635608A (en) * 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
TW200636066A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
AU2006203889A1 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. CRIPTO binding molecules
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
GT200600033A (en) * 2005-01-28 2006-10-25 POLYPEPTIDE STABILIZED LIQUID FORMULATIONS
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
EA015148B1 (en) 2005-06-17 2011-06-30 Элан Фарма Интернэшнл Лимитед METHODS OF PURIFYING Aβ BINDING PROTEIN HAVING A Fc REGION
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
TWI382990B (en) * 2005-12-12 2013-01-21 Hoffmann La Roche Antibody glycosylation in the variable region
JP5419131B2 (en) 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム Β1-42 specific monoclonal antibodies with therapeutic properties
TWI551607B (en) 2006-07-14 2016-10-01 Ａｃ免疫公司 Humanized antibody
AU2007308145A1 (en) * 2006-10-12 2008-04-17 Wyeth Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
WO2008070284A2 (en) 2006-10-16 2008-06-12 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute Amyloid beta peptides and methods of uses thereof
PT2426143T (en) * 2007-01-05 2017-09-22 Univ Zuerich Method of providing disease-specific binding molecules and targets
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith
JP2010515717A (en) * 2007-01-11 2010-05-13 フィリップス−ウニベルジテート・マールブルク Diagnosis and treatment of Alzheimer and other neurodementia disorders
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
BRPI0810118A8 (en) * 2007-04-18 2015-09-29 Janssen Alzheimer Immunotherap METHOD TO TREAT DISEASE, METHOD TO EFFECT CAA PROPHYLAXIS, USE OF AN AGENT, METHOD TO REDUCE VASCULAR AMYLOID IN A PATIENT, AND, KIT FOR TREATMENT
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
RS53174B (en) 2007-10-05 2014-06-30 Genentech Inc. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
CA2707309A1 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
SG186689A1 (en) * 2007-12-28 2013-01-30 Univ Tennessee Res Foundation Treatment and prophylaxis of amyloidosis
ES2617604T3 (en) 2008-02-08 2017-06-19 Immunas Pharma, Inc. Antibodies capable of specifically binding to beta amyloid oligomers, and their use
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
CA2724886C (en) 2008-05-23 2017-11-14 Siwa Corporation Methods, compositions and apparatuses for facilitating regeneration
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
SI2949666T1 (en) 2008-12-19 2019-03-29 Biogen International Neuroscience Gmbh Human anti-alpha-synuclein antibodies
US8614297B2 (en) * 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
ES2641612T3 (en) * 2009-04-17 2017-11-10 Immunas Pharma, Inc. Antibodies that specifically bind to beta A oligomers and use thereof
EP2462161B1 (en) 2009-08-06 2017-03-08 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
PL2475428T3 (en) 2009-09-11 2015-12-31 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CA2791648A1 (en) 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof
US8337845B2 (en) 2010-03-03 2012-12-25 Boehringer Ingelheim International Gmbh A-beta binding polypeptides
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012000094A1 (en) * 2010-06-30 2012-01-05 Mount Sinai Hospital REAGENTS AND METHODS FOR DIAGNOSING CONDITIONS ASSOCIATED WITH HYDROXYLATED HIF 1-α
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
US9649376B2 (en) 2010-09-27 2017-05-16 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
CA2839563C (en) 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
JP2012034697A (en) * 2011-09-16 2012-02-23 Janssen Alzheimer Immunotherapy HUMANIZED ANTIBODY RECOGNIZING β-AMYLOID PEPTIDE
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
KR102293064B1 (en) 2013-05-20 2021-08-23 제넨테크, 인크. Anti-transferrin receptor antibodies and methods of use
JP2014001232A (en) * 2013-09-02 2014-01-09 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic disease
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102438295B1 (en) 2014-09-19 2022-08-31 시와 코퍼레이션 Anti-age antibodies for treating inflammation and auto-immune disorders
CN107208076A (en) 2014-10-17 2017-09-26 科达制药 Butyrylcholine esterase amphoteric ion polymer conjugate
US10508151B2 (en) 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
MA41115A (en) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh ALZHEIMER'S DISEASE TREATMENT PROCESS
BR112017011234A2 (en) 2014-12-10 2018-03-27 Genentech Inc antibodies to the blood-brain barrier receptor and methods of use
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
KR20180020169A (en) 2015-06-24 2018-02-27 에프. 호프만-라 로슈 아게 Anti-transferrin receptor antibody with adjusted affinity
CN114057885A (en) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 Bispecific anti-human CD 20/human transferrin receptor antibodies and methods of use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CN108350052A (en) * 2015-11-09 2018-07-31 英属哥伦比亚大学 Epitope in amyloid beta intermediate region and its conformation antibodies selective
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004498A1 (en) * 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
JP2016047839A (en) * 2015-11-24 2016-04-07 ヤンセン・サイエンシズ・アイルランド・ユーシー Treatment of amyloidogenic disease
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. Antibodies and conjugates thereof
PT3337829T (en) 2016-02-19 2020-02-10 Siwa Corp Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
JP2020516648A (en) 2017-04-13 2020-06-11 シワ コーポレーション Humanized monoclonal advanced glycation end product antibody
CA3067597C (en) 2017-06-29 2023-03-21 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
RS64289B1 (en) 2017-08-22 2023-07-31 Biogen Ma Inc Pharmaceutical compositions containing anti-beta amyloid antibodies
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
AU2019354965A1 (en) 2018-10-04 2021-05-06 University Of Rochester Improvement of glymphatic delivery by manipulating plasma osmolarity
CN113227131A (en) 2018-12-20 2021-08-06 豪夫迈·罗氏有限公司 Modified antibody Fc and methods of use thereof
CN111518206B (en) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 Humanized anti-Abeta monoclonal antibody and application thereof
CN113692413A (en) 2019-04-02 2021-11-23 肯乔克蒂生物技术股份有限公司 Efflux pump-cancer antigen multispecific antibodies and compositions, reagents, kits and methods related thereto
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Methods of treating an eye disorder
CN116529267A (en) 2020-06-04 2023-08-01 肯乔克蒂生物技术股份有限公司 ABCG2 efflux pump-cancer antigen multispecific antibodies and related compositions, reagents, kits and methods
KR20230039734A (en) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 anti-Aβ antibody
TW202300517A (en) 2021-03-12 2023-01-01 美商美國禮來大藥廠 Anti-amyloid beta antibodies and uses thereof
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease

Family Cites Families (351)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096318A (en) 1973-05-07 2000-08-01 The Ohio State University Antigenically modified HCG polypeptides
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5158769A (en) 1984-03-07 1992-10-27 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4713366A (en) 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
US5096706A (en) 1986-03-25 1992-03-17 National Research Development Corporation Antigen-based treatment for adiposity
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5278049A (en) 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5220013A (en) 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5187153A (en) 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US4912206A (en) 1987-02-26 1990-03-27 The United States Of America As Represented By The Department Of Health And Human Services CDNA clone encoding brain amyloid of alzheimer's disease
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912506A (en) * 1987-06-10 1990-03-27 Brother Kogyo Kabushiki Kaisha Image recording apparatus having exposure unit
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5571500A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5641474A (en) 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
JP2512796B2 (en) 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド Treatment of autoimmune disease by oral administration of self-antigen
US5645820A (en) 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5869054A (en) 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
WO1989003687A1 (en) 1987-10-23 1989-05-05 Genetics Institute, Inc. Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene
US5089603A (en) 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
WO1989006689A1 (en) 1988-01-13 1989-07-27 The Mclean Hospital Corporation Genetic constructs containing the alzheimer brain amyloid gene
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
JPH04501719A (en) 1988-11-10 1992-03-26 インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド polypeptide
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5227159A (en) 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
WO1990012870A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
WO1990012871A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ES2144398T3 (en) 1989-12-20 2000-06-16 Autoimmune Inc IMPROVED TREATMENT OF AUTOIMMUNE DISEASES THROUGH THE ADMINISTRATION IN SELF-ANTIGEN SPRAY.
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
JPH05508621A (en) 1990-03-02 1993-12-02 オートイミューン　インク Down control of autoimmune diseases by oral administration of autoantigens
CA2079880A1 (en) 1990-04-24 1991-10-25 William E. Van Nostrand Purification, detection and methods of use of protease nexin-2
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
ATE153534T1 (en) 1990-04-27 1997-06-15 John Mcmichael METHOD AND COMPOSITION FOR TREATING CNS DISEASES CAUSED BY ABNORMAL BETA-AMYLOID PROTEIN
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
ES2217250T3 (en) 1990-06-15 2004-11-01 Scios Inc. TRANSGENIC, NON-HUMAN MAMMER THAT SHOWS THE AMILOID TRAINING PATHOLOGY OF ALZHEIMER'S DISEASE.
EP0537247A4 (en) 1990-06-19 1993-09-08 Immuvax Nonpathogenic variant virus
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
NZ239643A (en) 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US6506728B2 (en) 1990-09-25 2003-01-14 Genentech, Inc. Methods using a novel neurotrophic factor, NT-4
JPH06502071A (en) 1990-09-28 1994-03-10 ジ・アップジョン・カンパニー Transgenic animals carrying Alzheimer's amyloid precursor gene
ATE175118T1 (en) 1990-10-05 1999-01-15 Medarex Inc TARGETED IMMUNOSTIMULATION WITH BISPECIFIC SUBSTANCES
KR0140841B1 (en) 1990-10-15 1998-06-01 조앤 월리스 Treatment of autoimmune diseases by oral administration of autoantigens
GB9023352D0 (en) 1990-10-26 1990-12-05 Lynxvale Ltd Vaccinia vectors,vaccinia genes and expression products thereof
ATE286971T1 (en) 1991-01-21 2005-01-15 Elan Pharm Inc TEST AND MODEL FOR ALZHEIMERS DISEASE
CA2081660C (en) 1991-03-01 2001-05-01 Raymond Dufour Method for improving the organoleptic qualities of the meat from uncastrated male domestic animals and vaccine set for use in this method
US5192753A (en) 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
JPH06500128A (en) 1991-05-08 1994-01-06 シュバイツ・ゼルム―・ウント・インプフィンスティテュート・ベルン Immune stimulating and immunoenhancing reconstituted influenza virosomes and vaccines containing the same
DE69233254T2 (en) * 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5672805A (en) 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
AU671093B2 (en) 1992-01-07 1996-08-15 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
KR950700081A (en) 1992-02-11 1995-01-16 W 로우 죤 Dual Carrier Immunogenic Constructs
KR950700082A (en) 1992-02-28 1995-01-16 로버트 씨. 비숍 How to Treat Autoimmune Diseases by Bystander
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
GB9209118D0 (en) 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
PT652758E (en) 1992-06-18 2000-04-28 Harvard College DIFTERIA TOXIN VACCINES
CZ282235B6 (en) 1992-06-25 1997-06-11 Smithkline Beecham Biologicals (S.A.) Inoculation substance, process of its preparation and use
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
WO1994001772A1 (en) 1992-07-13 1994-01-20 The Children's Medical Center Corporation SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2127829T3 (en) 1992-07-31 1999-05-01 Medeva Holdings Bv EXPRESSION OF RECOMBINANT PROTEINS FUSED IN ATTENUATED BACTERIA.
ATE258188T1 (en) * 1992-08-27 2004-02-15 Deakin Res Ltd RETRO, INVERSO, AND RETRO-INVERSO SYNTHETIC PEPTIDE ANALOGS
US5958883A (en) 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
WO1994009364A1 (en) 1992-10-13 1994-04-28 Duke University Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein
US5605811A (en) 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
DK1298436T3 (en) 1992-10-26 2010-10-25 Elan Pharm Inc Process for Identifying Inhibitor Compounds for the Release of Beta-Amyloid Peptide (BAP)
US5972336A (en) 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP1360963B1 (en) 1993-01-22 2007-09-12 Sloan-Kettering Institute For Cancer Research Ganglioside-KLH conjugate vaccines with QS-21 for delaying recurrence of melanoma
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5472693A (en) 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
WO1994021680A1 (en) 1993-03-17 1994-09-29 The Government Of The United States Of America As Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
CA2158475C (en) 1993-03-18 2009-06-02 Lawrence Tamarkin Composition and method for reducing toxicity of biologically-active factors
PT812593E (en) 1993-03-23 2002-01-30 Smithkline Beecham Biolog VACCINES CONTAINING 3-O-DEACILED MONOPHOSPHALOR-LIPID IN ITS COMPOSITION
IT1270939B (en) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio PROCEDURE FOR THE PREPARATION OF IMMUNOGEN AND DIAGNOSTIC REAGENTS, AND IMMUNOGEN AND DIAGNOSTIC REAGENTS SO OBTAINABLE.
DK0705109T4 (en) 1993-05-25 2004-05-10 Wyeth Corp Adjuvants for vaccines against respiratory syncytial virus
AU7043894A (en) 1993-05-28 1994-12-20 Miriam Hospital, The Composition and method for (in vivo) imaging of amyloid deposits
PT700445E (en) 1993-06-04 2002-07-31 Whitehead Biomedical Inst STRESS PROTEINS AND THEIR USES
US5464823A (en) 1993-07-20 1995-11-07 The Regents Of The University Of California Mammalian antibiotic peptides
JPH09500540A (en) 1993-07-30 1997-01-21 メデヴァ ホールディングス ビー．ヴイ． Vaccine composition
WO1995005393A2 (en) 1993-08-18 1995-02-23 Morphosys Gesellschaft Für Proteinoptimierung Mbh Lipopolysaccharide-binding and neutralizing peptides
DK96493D0 (en) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps PROCEDURE FOR INDUCING ANTIBODY RESPONSE TO SELF-PROTEINS AND AUTOVACCINE PROCESSED BY THE PROCEDURE
AU707083B2 (en) 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
WO1995005853A1 (en) 1993-08-26 1995-03-02 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
WO1995006407A1 (en) 1993-08-30 1995-03-09 The Regents Of The University Of California Novel component of amyloid in alzheimer's disease and methods for use of same
CN1105728C (en) 1993-09-07 2003-04-16 史密丝克莱恩比彻姆公司 Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5652334A (en) 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
US5470951A (en) 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
ATE213507T1 (en) 1993-10-20 2002-03-15 Univ Duke METHOD FOR BINDING MATERIAL TO BETA-AMYLOID PEPTIDE
CA2172507C (en) 1993-10-22 2008-12-02 Jeffrey L. Cleland Methods and compositions for microencapsulation of antigens for use as vaccines
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
CA2182311A1 (en) * 1994-01-27 1995-08-03 Karen Hsiao Transgenic non-human mammals with progressive neurologic disease
CA2182731A1 (en) 1994-02-03 1995-08-10 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
AUPM411994A0 (en) 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
ATE202940T1 (en) 1994-05-25 2001-07-15 John Mcmichael MEANS AND METHODS FOR TREATING PLAQUE DISEASES
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5798100A (en) 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US6417178B1 (en) * 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
NZ290089A (en) 1994-07-27 1999-05-28 Queensland Inst Med Res Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines
DK0784684T3 (en) 1994-09-16 2007-12-17 Cancer Res Inst Of Contra Cost Recombinant peptides derived from the Mc3 anti BA46 antibody, methods for its use, and methods for humanizing antibody peptides
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
EP0820299B1 (en) 1995-02-06 2002-04-24 Genetics Institute, Inc. Formulations for il-12
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
ES2175083T3 (en) 1995-03-14 2002-11-16 Praecis Pharm Inc AMULOID AGGREGATION MODULATORS.
US5928913A (en) 1995-03-23 1999-07-27 Efstathiou; Stacey Vectors for gene delivery
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
ATE274064T1 (en) 1995-05-23 2004-09-15 Morphosys Ag MULTIMER PROTEINS
WO1996039176A1 (en) 1995-06-05 1996-12-12 Brigham & Women's Hospital USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
WO1996040895A1 (en) 1995-06-07 1996-12-19 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics using transgenic animal models
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US5910427A (en) 1995-06-22 1999-06-08 La Jolla Institute For Allergy And Immunology Antigen non-specific glycosylation inhibiting factor derivatives
ES2174027T3 (en) 1995-06-30 2002-11-01 American Cyanamid Co STABLE COMPOSITIONS CONTAINING MACROLIDES AND MACROLIDES COMBINED WITH VACCINES.
ATE305039T1 (en) 1995-07-07 2005-10-15 Darwin Molecular Corp GENE LOCALIZED ON CHROMOSOME 1 WHICH GENES PRODUCT IS ASSOCIATED WITH ALZHEIMER'S DISEASE.
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
AUPN443995A0 (en) 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
AU6898996A (en) 1995-08-21 1997-03-12 Cytrx Corporation Compositions and methods for growth promotion
ATE263374T1 (en) 1995-09-14 2004-04-15 Univ California ANTIBODIES SPECIFIC TO NATIVE PRP-SC
US5731284A (en) 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
EP0854919A1 (en) 1995-10-10 1998-07-29 Novartis AG Melanoma-associated protein
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
PT859959E (en) 1995-11-10 2003-12-31 Elan Corp Plc PEPTIDES THAT INCREASE TRANSPORTATION THROUGH TISSUES AND METHODS FOR THEIR IDENTIFICATION AND USES
WO1997018855A1 (en) 1995-11-21 1997-05-29 Eduard Naumovich Lerner Device for enhanced delivery of biologically active substances and compounds in an organism
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
WO1997032017A1 (en) 1996-02-26 1997-09-04 Morphosys Gesellschaft Für Proteinoptimierung Mbh Novel method for the identification of nucleic acid sequences encoding two or more interacting (poly)peptides
US6150091A (en) 1996-03-06 2000-11-21 Baylor College Of Medicine Direct molecular diagnosis of Friedreich ataxia
HUP9902438A3 (en) 1996-03-29 2000-03-28 Bayer Ag Parapoxvirus vectors
JP2000509022A (en) 1996-04-03 2000-07-18 アナージェン，インコーポレイテッド Cyclic peptide vaccine for the treatment and prevention of diabetes
AU735733B2 (en) 1996-04-19 2001-07-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Antigenically reactive regions of the hepatitis A virus polyprotein
US6284533B1 (en) 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
WO1998002462A1 (en) 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
GB9617616D0 (en) 1996-08-22 1996-10-02 Osteometer Biotech As Assaying protein fragments in body fluids
CA2183901A1 (en) 1996-08-22 1998-02-23 Johanna E. Bergmann Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
ES2245003T3 (en) 1996-08-27 2005-12-16 Praecis Pharmaceuticals Incorporated MODULATORS OF THE AGGREGATION OF BETA-AMYLOOID PEPTIDES THAT INCLUDE D-AMINO ACIDS.
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6797495B2 (en) 1996-11-05 2004-09-28 The Regents Of The University Of California Somatic cells with ablated PrP gene and methods of use
US6022859A (en) 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
US6962984B2 (en) 1996-12-05 2005-11-08 Nihon University IgA nephropathy-related DNA
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
EP0966447B1 (en) 1997-03-03 2003-03-05 Boehringer Ingelheim Pharmaceuticals Inc. Small molecules useful in the treatment of inflammatory disease
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5798102A (en) 1997-03-04 1998-08-25 Milkhaus Laboratory, Inc. Treatment of cardiomyopathy
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
SI0994728T1 (en) 1997-04-09 2009-02-28 Intellect Neurosciences Inc Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6787319B2 (en) * 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
ATE370740T1 (en) 1997-05-20 2007-09-15 Ottawa Health Research Inst METHOD FOR PRODUCING NUCLEIC ACID CONSTRUCTS
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
AU8269898A (en) 1997-06-27 1999-01-19 Regents Of The University Of California, The Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
IT1293511B1 (en) 1997-07-30 1999-03-01 Gentili Ist Spa MONOCLONAL CATALYTIC ANTIBODIES WITH PROTEASIC ACTIVITY FOR THE SELECTIVE LYSIS OF THE PROTEIN COMPONENT OF PLATES AND RELATED AGGREGATES
WO1999006545A2 (en) 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
CA2297070A1 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
CA2654522C (en) 1997-08-29 2014-01-28 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient
US6175057B1 (en) 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
US6118044A (en) * 1997-11-14 2000-09-12 Sankyo Company, Limited Transgenic animal allergy models and methods for their use
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
DE69831971T2 (en) 1997-12-03 2006-07-06 Neuralab Ltd., Flatts SUPPRESSION OF CHANGES ASSOCIATED WITH BETA AMYLOID AT ALZHEIMER
BR9815345A (en) 1997-12-03 2000-11-21 Fujisawa Pharmaceutical Co Soft composition of pelleted drug, inhaler using it and method for its manufacture
FR2777015B3 (en) 1998-02-23 2000-09-15 Financ De Biotechnologie METHOD AND MEANS FOR OBTAINING CELLULAR AND ANIMAL MODELS OF NEURODEGENERATIVE DISEASES
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
EP1073464B1 (en) 1998-04-28 2004-10-06 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
NO314086B1 (en) 1998-05-08 2003-01-27 Gemvax As Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for
JP2003532618A (en) 1998-05-19 2003-11-05 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド Cells, nervous system-specific antigens and their uses
JP2002515235A (en) 1998-05-21 2002-05-28 ザ ユニヴァーシティ オブ テネシー リサーチ コーポレイション Amyloid removal method using anti-amyloid antibody
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6432710B1 (en) 1998-05-22 2002-08-13 Isolagen Technologies, Inc. Compositions for regenerating tissue that has deteriorated, and methods for using such compositions
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
JP2002526419A (en) 1998-10-05 2002-08-20 ファーメクサ エイ／エス Novel methods for therapeutic vaccination
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
US7112661B1 (en) 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
EP1148891B1 (en) 1999-01-19 2004-03-17 PHARMACIA & UPJOHN COMPANY Method of packaging an oxidation sensitive medicinal substance
JP2002535289A (en) 1999-01-22 2002-10-22 ドウアリング，マシユー・ジヨン Vaccine-mediated treatment of neurological disorders
US7629311B2 (en) 1999-02-24 2009-12-08 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US7282570B2 (en) 1999-04-20 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2000068263A2 (en) 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AR024558A1 (en) 1999-06-01 2002-10-16 Neuralab Ltd COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME
DE60040024D1 (en) 1999-06-16 2008-10-02 Boston Biomedical Res Inst IMMUNOLOGICAL CONTROL OF THE BETA-AMYLOID CONTENT IN VIVO
EP1368486A4 (en) 1999-07-15 2009-04-01 Genetics Inst Llc Formulations for il-11
JP4796725B2 (en) 1999-08-04 2011-10-19 ユニバーシティ オブ サザン カリフォルニア Amyloid β protein (spherical assembly and use thereof)
DE60044057D1 (en) 1999-09-03 2010-05-06 Univ Ramot COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ALZHEIMER DISEASE
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
AU784312B2 (en) 1999-11-29 2006-03-09 Bellus Health (International) Limited Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
ES2275570T3 (en) 1999-12-08 2007-06-16 Intellect Neurosciences, Inc. BETA CHEMERIC AMYLOID PEPTIDES.
US6399314B1 (en) * 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
AU783144B2 (en) 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
CN1279971C (en) 2000-02-21 2006-10-18 法麦克萨有限公司 Novel method for down-regulation of amyloid
SK288723B6 (en) * 2000-02-24 2020-01-07 Univ Washington Pharmaceutical preparation and use of said pharmaceutical preparation
AU2001253158A1 (en) 2000-04-05 2001-10-23 University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis
EP1385541B1 (en) 2000-04-13 2008-06-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
ATE286072T1 (en) 2000-05-22 2005-01-15 Univ New York SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGUE TO AMYLOID BETA AND THEIR USE TO INDUCE AN IMMUNE RESPONSE AGAINST AMYLOID BETA AND AMYLOID AGGREGATES
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
ATE441663T1 (en) * 2000-09-06 2009-09-15 Aventis Pharma Sa METHODS AND COMPOSITIONS FOR AMYLOIDOSIS-RELATED DISEASES
IT1319277B1 (en) 2000-10-24 2003-09-26 Chiesi Farma Spa MELTING PROTEINS USEFUL FOR ALZHEIMER'S MILK IMMUNIZATION TREATMENT.
IL139308A0 (en) 2000-10-26 2001-11-25 Marikovsky Moshe Peptides from amyloid precursor protein which inhibit tumor growth and metastasis
EP1347731B1 (en) 2000-11-02 2007-04-25 Cornell Research Foundation, Inc. In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease
PT1346041E (en) 2000-11-27 2007-06-05 Praecis Pharm Inc Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
PE20020574A1 (en) * 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6900036B2 (en) 2000-12-27 2005-05-31 University Of Texas Health Science Center Houston Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers
WO2002059621A2 (en) 2001-01-24 2002-08-01 Bayer Corporation Regulation of transthyretin to treat obesity
DE60121729T2 (en) 2001-04-19 2007-11-29 Dr. Hermann Schätzl Prion protein dimers for vaccinations
ATE420114T1 (en) 2001-04-30 2009-01-15 Lilly Co Eli HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA-AMYLOID PEPTIDE&X9;
DE60229051D1 (en) * 2001-04-30 2008-11-06 Lilly Co Eli HUMANIZED ANTIBODIES
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20020197258A1 (en) 2001-06-22 2002-12-26 Ghanbari Hossein A. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
US20030135035A1 (en) 2001-08-09 2003-07-17 Mark Shannon Human ZZAP1 protein
EP1519740A4 (en) 2001-08-17 2005-11-09 Lilly Co Eli Rapid improvement of cognition in conditions related to a-beta
CA2452104A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US6907297B2 (en) 2001-09-28 2005-06-14 Ethicon, Inc. Expandable intracardiac return electrode and method of use
US7781413B2 (en) 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
CA2466841A1 (en) 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
AU2002366355A1 (en) 2001-12-17 2003-06-30 New York State Office Of Mental Health SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
BR0312792A (en) 2002-07-19 2005-05-03 Cytos Biotechnology Ag Vaccine compositions containing beta1-6 amyloid antigenic series
EP1911765A3 (en) 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
JP2006508072A (en) 2002-10-01 2006-03-09 ノースウエスタン ユニバーシティ Amyloid beta-derived diffusible ligands (ADDLs), ADDL substitutes, ADDL-binding molecules, and uses thereof
US20060019850A1 (en) 2002-10-31 2006-01-26 Korzenski Michael B Removal of particle contamination on a patterned silicon/silicon dioxide using dense fluid/chemical formulations
FR2846667B1 (en) 2002-11-06 2004-12-31 Pasteur Institut VARIABLE FRAGMENTS OF SINGLE-CHAIN CAMELIDE ANTIBODIES DIRECTED AGAINST BETA-AMYLOID PEPTIDE 1-42 AND THEIR APPLICATIONS FOR DIAGNOSIS AND TREATMENT OF NEUROAGREGATIVE DISEASES
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US6787129B1 (en) 2003-01-13 2004-09-07 Zenitech Llc Castor polyester as gloss agents in anionic systems
CA2513722A1 (en) 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
US7575747B2 (en) 2003-02-10 2009-08-18 Applied Molecular Evolution Aβ binding molecules
PT1610820E (en) 2003-04-04 2010-12-16 Novartis Ag High concentration antibody and protein formulations
EP1480041A1 (en) 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20060182321A1 (en) 2003-07-07 2006-08-17 Agency For Science, Technology And Research Method and apparatus for extracting third ventricle information
WO2005014041A2 (en) 2003-07-24 2005-02-17 Novartis Ag Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
EP1670827A2 (en) 2003-09-05 2006-06-21 Eli Lilly And Company Anti-ghrelin antibodies
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
MXPA06006821A (en) 2003-12-17 2006-08-23 Elan Pharm Inc Abeta IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME.
EP1701968B1 (en) 2003-12-17 2015-06-03 Wyeth LLC Immunogenic peptide carrier conjugates and methods of producing same
US20050214222A1 (en) 2004-02-13 2005-09-29 Mckinnon Stuart J In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes
AU2005270026A1 (en) 2004-07-02 2006-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of thioflavin radiolabeled derivatives in amyloid imaging for assessing anti-amyloid therapies
SG190665A1 (en) 2004-07-30 2013-06-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
EP1797182A2 (en) 2004-10-05 2007-06-20 Wyeth a Corporation of the State of Delaware Methods and compositions for improving recombinant protein production
US20060160161A1 (en) 2004-10-26 2006-07-20 Elan Pharmaceuticals, Inc. Methods for assessing antibodies to neurodegenerative disease-associated antigens
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
TW200635608A (en) 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2006066233A1 (en) 2004-12-15 2006-06-22 Neuralab Limited An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
US20060153772A1 (en) 2004-12-15 2006-07-13 Wyeth Contextual fear conditioning for predicting immunotherapeutic efficacy
GT200600033A (en) 2005-01-28 2006-10-25 POLYPEPTIDE STABILIZED LIQUID FORMULATIONS
GT200600031A (en) 2005-01-28 2006-08-29 ANTI-BETA ANTIBODY FORMULATION
EA015148B1 (en) 2005-06-17 2011-06-30 Элан Фарма Интернэшнл Лимитед METHODS OF PURIFYING Aβ BINDING PROTEIN HAVING A Fc REGION
EP1910364B1 (en) 2005-07-18 2012-03-21 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007059000A2 (en) 2005-11-10 2007-05-24 Roskamp Research, Llc Modulation of angiogenesis by a-beta peptide fragments
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
WO2010044803A1 (en) 2008-10-17 2010-04-22 Elan Pharma International Limited Treatment of amyloidogenic diseases
EP2120717A1 (en) 2007-03-12 2009-11-25 National Institute of Radiological Sciences Pet visualization of amyloid-associated neuroinflammation in the brain
BRPI0810118A8 (en) 2007-04-18 2015-09-29 Janssen Alzheimer Immunotherap METHOD TO TREAT DISEASE, METHOD TO EFFECT CAA PROPHYLAXIS, USE OF AN AGENT, METHOD TO REDUCE VASCULAR AMYLOID IN A PATIENT, AND, KIT FOR TREATMENT
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
DK2323696T3 (en) 2008-09-18 2018-11-26 Cedars Sinai Medical Center OPTICAL PROCEDURE FOR DETECTING ALZHEIMER'S DISEASE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642044B2 (en) 1997-12-02 2014-02-04 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US9051363B2 (en) 1997-12-02 2015-06-09 Janssen Sciences Ireland Uc Humanized antibodies that recognize beta amyloid peptide
US8535673B2 (en) 1997-12-02 2013-09-17 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US7893214B2 (en) 1997-12-02 2011-02-22 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US8034339B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8034348B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US8128928B2 (en) 2002-03-12 2012-03-06 Wyeth Llc Humanized antibodies that recognize beta amyloid peptide
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US7871615B2 (en) 2003-05-30 2011-01-18 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8318164B2 (en) 2005-01-28 2012-11-27 Janssen Alzheimer Immunotherapy Anti A beta antibody formulation
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies

Also Published As

Publication number Publication date
KR20110027846A (en) 2011-03-16
UA89469C2 (en) 2010-02-10
CA2478049A1 (en) 2003-09-25
EP1554311A4 (en) 2007-04-11
KR101122871B1 (en) 2012-06-01
EP1554311A2 (en) 2005-07-20
CN1703426B (en) 2010-04-28
AU2003214152B2 (en) 2009-08-27
US20110142823A1 (en) 2011-06-16
SG180018A1 (en) 2012-05-30
CN1703426A (en) 2005-11-30
CO5611164A2 (en) 2006-02-28
US20040082762A1 (en) 2004-04-29
BR0308143A (en) 2007-01-23
HK1085222A1 (en) 2006-08-18
GEP20084474B (en) 2008-09-10
MXPA04008740A (en) 2005-07-13
KR20050071368A (en) 2005-07-07
US7256273B2 (en) 2007-08-14
AU2003214152A1 (en) 2003-09-29
US8128928B2 (en) 2012-03-06
WO2003077858A2 (en) 2003-09-25
EA010902B1 (en) 2008-12-30
ZA200406616B (en) 2006-10-25
TW200307130A (en) 2003-12-01
IS7499A (en) 2004-10-11
PL375159A1 (en) 2005-11-28
ES2389541T3 (en) 2012-10-29
CA2478049C (en) 2012-09-25
EP1554311B1 (en) 2012-06-13
NO20043992L (en) 2004-09-23
EA200401170A1 (en) 2005-10-27
JP2006503549A (en) 2006-02-02
PL215258B1 (en) 2013-11-29
AR038953A1 (en) 2005-02-02
TWI328116B (en) 2010-08-01
IL163626A0 (en) 2005-12-18
MY139983A (en) 2009-11-30
ECSP045314A (en) 2005-07-06
IL163626A (en) 2011-12-29
UY27721A1 (en) 2003-09-30
NZ535769A (en) 2009-02-28
PE20040207A1 (en) 2004-04-13
HRP20040950A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
WO2003077858A3 (en) Humanized antibodies that recognize beta amyloid peptide
WO2004080419A3 (en) Humanized antibodies that recognize beta amyloid peptide
WO2004108895A3 (en) Humanized antibodies that recognize beta amyloid peptide
WO2006066049A3 (en) Humanized antibodies that recognize beta amyloid peptide
WO2002046237A3 (en) Humanized antibodies that recognize beta amyloid peptide
TW200635607A (en) Humanized Aβ antibodies for use in improving cognition
GEP20115195B (en) Antibodies directed against amyloid-beta peptide and use thereof
WO2006118959A3 (en) Antibodies directed against amyloid-beta peptide and methods using same
IL165193A (en) Humanized immunomodulatory monoclonal antibodies and use thereof for the treatment of neoplastic disease
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
TW200501982A (en) Immunoglobulin variants and uses thereof
WO2005003298A3 (en) Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease
MXPA05010914A (en) Alzheimer's disease treatment method.
AUPS255202A0 (en) Agents and methods for the treatment of disorders associated with motor neuron degeneration
AU2003240746A8 (en) Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
TH83888B (en) Humanized beta-amyloid peptide specific antibodies
AU2003229380A1 (en) Agents and methods for the treatment of disorders associated with motor neuron degeneration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004/06616

Country of ref document: ZA

Ref document number: 163626

Country of ref document: IL

Ref document number: 200406616

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2450/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003214152

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2478049

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003575912

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/008740

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 375159

Country of ref document: PL

Ref document number: 1020047014176

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038058162

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 535769

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1200401015

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200401170

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1-2004-501406

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 8440

Country of ref document: GE

Ref document number: 2003711559

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P20040950A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 1020047014176

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003711559

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: PI0308143

Country of ref document: BR